Chinanews.com, February 15th. According to news from the website of the State Drug Administration on the 15th, the State Drug Administration recently approved the listing of the Class 1 innovative drug Caprazan Hydrochloride Tablets declared by Jiangsu Kefeiping Pharmaceutical Co., Ltd.
The drug is suitable for the treatment of duodenal ulcer and reflux esophagitis.
Capraxan hydrochloride is a new type of potassium ion competitive acid blocker, which inhibits gastric acid secretion by binding to the K+ binding site on H+-K+-ATPase.
The launch of the drug provides a new treatment option for patients with duodenal ulcer and reflux esophagitis.
(China New Finance and Economics)
Picture from the website of the State Food and Drug Administration